1. Home
  2. PRAX vs GGAL Comparison

PRAX vs GGAL Comparison

Compare PRAX & GGAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$289.43

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Logo Grupo Financiero Galicia S.A.

GGAL

Grupo Financiero Galicia S.A.

HOLD

Current Price

$42.04

Market Cap

7.4B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
GGAL
Founded
2015
1905
Country
United States
Argentina
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Commercial Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
7.4B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
PRAX
GGAL
Price
$289.43
$42.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
4
Target Price
$572.13
$69.00
AVG Volume (30 Days)
308.0K
1.1M
Earning Date
05-01-2026
03-07-2023
Dividend Yield
N/A
3.38%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$50.70
Revenue Next Year
$6,395.88
N/A
P/E Ratio
N/A
$13.36
Revenue Growth
N/A
N/A
52 Week Low
$26.70
$25.89
52 Week High
$354.87
$66.24

Technical Indicators

Market Signals
Indicator
PRAX
GGAL
Relative Strength Index (RSI) 37.95 39.62
Support Level $266.93 $25.97
Resistance Level $322.32 $45.86
Average True Range (ATR) 16.36 2.01
MACD -4.02 -0.05
Stochastic Oscillator 4.20 26.16

Price Performance

Historical Comparison
PRAX
GGAL

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About GGAL Grupo Financiero Galicia S.A.

Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.

Share on Social Networks: